Plus Therapeutics
PSTVPlus Therapeutics is a clinical-stage pharmaceutical company focused on developing and commercializing precision diagnostics and targeted radiopharmaceuticals for central nervous system (CNS) cancers.
Table of contents
Earnings
Next report
Aug 13, 2026 (In 2 weeks)Competitors
By market cap
By revenue growth
Profile
Plus Therapeutics is a clinical-stage pharmaceutical company focused on developing and commercializing precision diagnostics and targeted radiopharmaceuticals for central nervous system (CNS) cancers. The company leverages a proprietary nanoliposomal platform to deliver high-dose radiation directly to tumors while minimizing exposure to healthy tissue. Its core value proposition lies in combining advanced diagnostic assays with localized radiotherapy to improve outcomes for patients with rare and lethal brain and spinal cancers.
A specialized developer of CNS-focused radiotherapeutics with Fast Track and Orphan Drug designations for its lead candidates.
Questions, answered.
- What is Plus Therapeutics's market cap?
- Plus Therapeutics (PSTV) has a market capitalization of $25.7M and trades on NASDAQ.
- Who are Plus Therapeutics's competitors?
- Plus Therapeutics's key competitors include NeoGenomics, LabCorp, Pfizer, and others. These companies compete in similar markets and product categories.
- Who does Plus Therapeutics partner with?
- Plus Therapeutics's notable partners include UnitedHealthcare Insurance Company, Humana, Inc., K2bio, and others.
- What subsidiaries does Plus Therapeutics have?
- Plus Therapeutics's subsidiaries include CNSide Diagnostics, LLC.
- Where is Plus Therapeutics headquartered?
- Plus Therapeutics is headquartered in United States of America and employs approximately 20 people. It has been publicly traded since 2000.